Compare Amphastar Pharmaceuticals Inc (AMPH) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Lululemon Athletica Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Lululemon Athletica Inc trades at $119.18 (market cap $13.54B). The key difference: Lululemon Athletica Inc is far larger — about 16.4× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | LULU | |
|---|---|---|
Market Cap | $826.08M | $13.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $236.51 |
52-Week Low | $16.87 | $105.43 |
Enterprise Value | $1.22B | $14.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Lululemon (LULU) trades at $119.26, up 2.36% on the day, showing resilience amid a challenging year where the stock has declined significantly from its highs. The technical picture is neutral with mixed signals from moving averages and oscillators, while fundamentals remain strong with consistent earnings beats, a P/E of 9.66, and robust profitability margins. Recent news highlights board stability after a proxy settlement but also ongoing consumer lawsuits and brand controversies.
The outlook is cautiously optimistic; valuation appears attractive relative to historical levels, and international growth provides upside potential. However, risks include North American market weakness, intense competition, and brand reputation concerns. Analyst consensus leans hold with a $130.53 price target, suggesting moderate upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
